PubMed Health⌕ Search

PubMed · 7606868

CD40 ligand expression is developmentally regulated in human thymocytes.

Abstract

Thymic selection involves the interaction between developing thymocytes and the thymic microenvironment. CD40 is expressed on thymic epithelial cells and on bone marrow-derived antigen-presenting cells in the thymus. We have investigated the capacity of human thymocytes to express CD40 ligand. CD40 ligand was not detectable on resting immature double-positive (CD4+/CD8+) or resting mature single-positive (CD4+/CD8- or CD4-/CD8+) thymocytes. Immature thymocytes failed to express CD40 ligand on their surface after stimulation with PMA and ionomycin, whereas stimulated CD4+/CD8- mature thymocytes expressed CD40 ligand. Northern blot analysis revealed that CD40 ligand mRNA was detectable in activated mature single-positive thymocytes. CD40 ligand expression by mature thymocytes was associated with the capacity to drive immunoglobulin isotype switching in purified B cells. These results demonstrate that the ability to express CD40 ligand is acquired late in thymocyte development and that mature thymocytes are capable of providing B cells with the activation signals necessary for immunoglobulin isotype switching.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R Fuleihan, D Ahern, R S Geha. 1995. CD40 ligand expression is developmentally regulated in human thymocytes.. https://doi.org/10.1006/clin.1995.1087

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Autophagic-like cell death in neutrophils induced by autoantibodies.

Human neutrophils undergo autophagic-like cell death following Sialic acid binding immunoglobulin-like lectin-9 (Siglec-9) ligation and concurrent stimulation with certain, but not all, neutrophil survival cytokines. Caspase inhibition by these cytokines is required, but is not sufficient, to trigger this particular form of cell death. Additional mechanisms may involve reactive oxygen species (ROS), and blocking of ROS or prevention of ROS production prevents autophagic-like neutrophil death. Interestingly, human intravenous immunoglobulin (IVIg) preparations contain natural anti-Siglec-9 autoantibodies, which are able to ligate Siglec-9 on neutrophils and induce autophagic-like cell death in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) and some other survival cytokines. Here, we discuss the pathophysiological and therapeutic implications of these recent findings.

Antigens, CD↗

Bias in association studies of systemic lupus erythematosus susceptibility due to geographical variation in the frequency of a programmed cell death 1 polymorphism across Europe.

We obtained eight collections of DNA samples from ethnically matched systemic lupus erythematosus (SLE) patients and controls from five European countries totaling 783 patients and 1210 controls. A highly significant cline in the frequency of the PD1.3 A allele was found among controls but not among SLE patients. The frequency of the PD1.3 A allele increased from the Northeast to the Southwest of Europe. The cline was clearly apparent (P=1.2 x 10(-6)) when data from controls of other five SLE susceptibility studies were included in the analysis. This variation has severely biased SLE association studies owing to the lack of parallel changes in SLE patients. As a consequence, the PD1.3 A allele was more common in SLE patients than in controls in the Northeast and Center of Europe, similar to controls in Southeast Europe, and less frequent than in the controls in the Southwest of the Continent. This dissociation in allele frequencies between SLE patients and controls in different subpopulations indicated that programmed cell death 1 variation and disease susceptibility are not independent but the type of relationship is currently unclear. As allele frequency clines are common in other polymorphisms their impact in genetic epidemiology studies should be carefully considered.

Antigens, CD↗